NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 1,231.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 239,283 shares of the company's stock after buying an additional 221,305 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.27% of NewAmsterdam Pharma worth $3,972,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Decheng Capital LLC bought a new position in shares of NewAmsterdam Pharma in the 2nd quarter valued at about $7,684,000. Millennium Management LLC raised its position in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock valued at $22,388,000 after purchasing an additional 217,902 shares during the period. Deerfield Management Company L.P. Series C lifted its stake in shares of NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock valued at $16,698,000 after purchasing an additional 202,250 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of NewAmsterdam Pharma by 47.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 423,155 shares of the company's stock worth $8,129,000 after purchasing an additional 136,955 shares during the period. Finally, FMR LLC increased its position in shares of NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company's stock valued at $5,485,000 after purchasing an additional 86,712 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock traded down $0.40 on Friday, hitting $24.69. 1,405,221 shares of the company traded hands, compared to its average volume of 365,292. The stock's 50 day moving average price is $20.40 and its 200-day moving average price is $18.68. NewAmsterdam Pharma has a 52 week low of $9.72 and a 52 week high of $27.29.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the transaction, the insider now owns 11,812,033 shares of the company's stock, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock worth $1,755,307 in the last ninety days. 19.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several recent analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reiterated a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Scotiabank boosted their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a research report on Wednesday. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $36.20.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.